Physician profile
Esther Langner
NPI 1649947763
$2,453.02
in general payments reported to CMS, 2019-2025
16 companies · $573 in 2025
The $573 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $295 · 2023: $1,028 · 2024: $558 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,158.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $658.25 | 2022-2025 | |
| Incyte Corporation | $414.33 | 2022-2025 | Opzelura |
| Genzyme Corporation | $364.05 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $255.49 | 2022-2025 | Dupixent |
| Amgen INC. | $119.99 | 2022-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $119.93 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $96.66 | 2023-2025 | |
| Lilly USA, LLC | $93.47 | 2024-2025 | Ebglyss, Olumiant, Taltz |
| Galderma Laboratories, L.P. | $65.75 | 2022-2023 | |
| Dermavant Sciences, INC. | $52.46 | 2023 | Vtama |
| Pfizer INC. | $49.83 | 2023 | |
| Janssen Biotech, INC. | $46.34 | 2023-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $42.11 | 2025 | |
| Botanix Sb INC | $30.19 | 2025 | Sofdra |
| Lnhc, INC | $25.00 | 2025 | Zelsuvmi |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $19.17 | 2025 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Langner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.